Drugs / Vasoactive Intestinal Peptide
Vasoactive Intestinal Peptide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00004494 | Sep 1998 → ? | adult acute respiratory distress syndrome, infectious disease with sepsis | Stony Brook University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00272896 | Oct 2004 → Sep 2005 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| — | NCT04260035 Comparator | May → Sep 2020 | migraine without aura | Danish Headache Center | Completed | No outcome recorded |
| — | NCT03989817 Comparator | Jun 2019 → Jun 2020 | headache disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT01471990 Comparator | May 2011 → Jun 2012 | migraine without aura | Glostrup University Hospital, Copenhagen | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vasoactive Intestinal Peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03989817 ↗ |
| Known as | vasoactive intestinal polypeptide | “including the vasoactive intestinal polypeptide (VIP),” PMID 35432170 ↗ Apr 2022 |
| Known as | VIP | “The purpose of this study is to examine and compare the effect of pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) and vasoactive intestinal polypeptide (VIP) on...” NCT01471990 ↗2“Patients receive vasoactive intestinal peptide (VIP) IV over either 6 or 12 hours.” NCT00004494 ↗ “including the vasoactive intestinal polypeptide (VIP),” PMID 35432170 ↗ Apr 2022 |
| Modality | Peptide | “Evaluate the safety and pharmacodynamic activity of this peptide in these patients.” NCT00004494 ↗ |
| Route | Intravenous | “Patients receive vasoactive intestinal peptide (VIP) IV over either 6 or 12 hours.” NCT00004494 ↗ |